Biotech Values

[palindromy]

Thanks for the detailed info.
I can see the question has been raised before.

I just listened to PSDVs R&R presentation, it does seem that a previous device (Retisert) with the same drug has beaten laser in a randomized trial. According to mgmt, the reason that trial could not be pivotal is that it was surgical procedure v laser (as opposed to current trial which uses sham injection as a placebo).
With respect to competition mgmt highlights Allergan as nearest competitor with a similar device/drug combo. However, they seem to require injections every six months.

I do fully take on board that neither PSDV nor their partner seem to have the financial resources to be successful, but given Pfizer as a shareholder, I would think a restructured deal is always possible if clinical trials are successful.

Bottom line, even with all the risks, seems like the market cap of 60m odd is relatively cheap. It might be momo until Dec, but as wallstarb repeatedly points out, it does not change the color of money!